Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cisplatin + gemcitabine followed by concurrent chemoradiation in locally advanced cervical cancer
2008-006309-17Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in Cervical Cancer (CC), sponsored by National Cancer Institute. Primary endpoints: Efficacy of neoadjuvant chemotherapy + concurrent chemoradiation, Safety of neoadjuvant chemotherapy + concurrent chemoradiation and 1 more. Started Jun 2009; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2008-006309-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006309-17.